| 2023/09/22 17:35:06 | |
|---|---|
| Price | |
| 0.29 EUR | |
| Difference | 1.05% (0.00) |
General attributes
| ISIN | BE0974281132 |
| Symbol | - |
| Exchange | Euronext Brussels |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 27 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | - (350) |
| Ask (Ask size) | - (567,930) |
| Open | 0.29 EUR |
| High | 0.293 EUR |
| Low | 0.287 EUR |
| Close (prev. day) | 0.287 EUR |
| VWAP | 0.290735 EUR |
| Volume (pcs) | 112,228 |
| Trading volume | 32,629.00 |
| Number of trades | 72 |
| Last size | 504 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: BIOCARTIS GROUP NV |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/07/12 |
|
Global Equity Ratings |
|
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2024/05/29 |
|
Global Equity Ratings |
|
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2023/09/22 17:35:06 | |
|---|---|
| Price | |
| 0.29 EUR | |
| Difference | 1.05% (0.00) |
General attributes
| ISIN | BE0974281132 |
| Symbol | - |
| Exchange | Euronext Brussels |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 27 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | - (350) |
| Ask (Ask size) | - (567,930) |
| Open | 0.29 EUR |
| High | 0.293 EUR |
| Low | 0.287 EUR |
| Close (prev. day) | 0.287 EUR |
| VWAP | 0.290735 EUR |
| Volume (pcs) | 112,228 |
| Trading volume | 32,629.00 |
| Number of trades | 72 |
| Last size | 504 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -52.38% | -67.08% | -92.64% |
| Perf (abs.) | -0.32 | -0.59 | -3.65 |
| Beta | 0.00 | -0.01 | 0.74 |
| Volatility | 55.29 | 68.77 | 54.68 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 0.29 EUR (105,754) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 0.32 EUR (119,910) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 0.41 EUR (173,151) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 0.60 EUR (168,545) |
| YTD High | date | 0.79 EUR (2023/04/14) |
| YTD Low | date | 0.28 EUR (2023/09/19) |
| 52 Weeks High | date | 1.27 EUR (2022/10/19) |
| 52 Weeks Low | date | 0.28 EUR (2023/09/19) |
All listings for BIOCARTIS GROUP NV
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Stuttgart | 2023/09/25 | 08:07 | 0.2595 EUR | 0.00 | 3 |
| London Stock Exchange European Trade Reporting | 2023/09/25 | 17:30 | 0.299 EUR | 0.00 | 2 |
| Frankfurt | 2023/09/25 | 08:08 | 0.2595 EUR | 0.00 | 1 |
| FINRA other OTC Issues | 2022/12/09 | 19:40 | 0.66 USD | 0.00 | 1 |
| Euronext Brussels | 2023/09/22 | 17:35 | 0.29 EUR | 0.03 | 72 |
| Duesseldorf | 2023/09/25 | 08:11 | 0.2585 EUR | 0.00 | 1 |
| Berlin | 2023/09/25 | 08:22 | 0.2895 EUR | 0.00 | 1 |
Company Logo
Contact Details
| BIOCARTIS GROUP NV |
| - - |
| Generaal de Wittelaan 11B - 2800 Mechelen |
| Telefon: +32-1-563-26-00 |
| Fax: + |
| E-mail: info@biocartisgroupnv.be |
PDF Downloads
| Company report: BIOCARTIS GROUP NV | |
Company Profile
Biocartis Group NV engages in the development of personalized medicine for patients around the world. It also focuses on developing and commercializing oncology tests. The company was founded by Philippe Renaud, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium. |
Members of Management Board
| Roger Moody | Chairman of Managing Board |
| George Cardoza | Member of Executive Committee |
| Piet Houwen | Member of Executive Committee |
Board of directors
| Herman Verrelst | Chairman of Supervisory Board |
| Bryan DeChairo | Member of Supervisory Board |
| Christian Reinaudo | Member of Supervisory Board |
| Christine Kuslich | Member of Supervisory Board |
| Ann-Christine M. Sundell | Member of Supervisory Board |
| Luc Gijsens | Member of Supervisory Board |